Listen to the news

Two new strategic investments for scientific industrial research with a total budget of over 89 million euros have been approved by the Greek Interdepartmental Committee for Strategic Investments (DESE), reports BTA.

The organizer of both investments is the pharmaceutical company Demo (DEMO SA), which is engaged in the development, production and marketing of pharmaceutical products. 

The investments will be made in the company's industrial sites in Thermi, Municipality of Thessaloniki, and in Krioneri, near Athens, where a site is to be built.

They were approved yesterday and concern two projects for scientific industrial research and the development of two monoclonal antibodies for biological therapy in the treatment of malignant neoplasms. 

Europe is running out of drugs

The objective of the first project worth €44,690,600 is to approve and market the first biosimilar pharmaceutical product for oncology treatment from a Greek company, which can be used in a number of oncological diseases. 

The second investment project with a total budget of EUR 44,433,967 will aim at the approval and marketing of the first Greek biosimilar pharmaceutical product for the oncological treatment of multiple myeloma. 

"I am extremely proud that (…) one of the largest investments in our history in the pharmaceutical sector has been approved and its implementation is beginning.

An investment that will bring jobs, research and technology and great progress to our country," said Greek Minister of Development and Investments Adonis Georgiadis. 

Greece

the pharmaceutical sector